Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for non-diabetic chronic kidney disease
ACTRN12622000265774Phase 3Not yet recruiting
- Sponsor
- Zara Nisar
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Zara Nisar. Primary endpoint: Change in estimated glomerular filtration rate from baseline at 90 days. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12622000265774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000265774.